Incremental Health Care Burden of Bleeding Among Patients with Venous Thromboembolism in the United States.

@article{Amin2015IncrementalHC,
  title={Incremental Health Care Burden of Bleeding Among Patients with Venous Thromboembolism in the United States.},
  author={Alpesh N Amin and Amanda S. Bruno and Jeffrey N Trocio and Jay Lin and Melissa Lingohr-Smith},
  journal={Journal of managed care \& specialty pharmacy},
  year={2015},
  volume={21 10},
  pages={
          965-72
        }
}
BACKGROUND The health care and economic burden of venous thromboembolism (VTE) has been evaluated in regard to acute VTE, VTE recurrence, and some VTE complications, such as postthrombotic syndrome, but the cost burden attributed to bleedings is not well understood. OBJECTIVE To evaluate health care resource utilization and costs associated with major bleeding (MB) and clinically relevant nonmajor bleeding (CRNMB) among a large U.S. commercially and Medicare-insured population with VTE… 
Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population
TLDR
Warfarin was associated with significantly higher risk of MB and CRNM bleeding as well as higher MB-related and all-cause costs vs apixaban patients and recurrent VTE risk and costs were similar among warfarin and apxaban patients.
Evaluation of the Incremental Healthcare Economic Burden of Patients with Atrial Fibrillation Treated with Direct-Acting Oral Anticoagulants and Hospitalized for Major Bleeds in the USA
TLDR
Among a large US nationally representative sample of patients with atrial fibrillation treated with DOACs, the cost of MB hospitalization was substantial and healthcare costs following MB events were nearly 40% higher compared to those of Patients with AF without an MB.
Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients
TLDR
When any of the four NOACs are used instead of standard therapy for acute VTE, treatment medical costs are reduced, and Apixaban is associated with the greatest reduction in medical costs.
Economic Evaluations of Medical Cost Differences: Use of Targeted-SpecificOral Anticoagulants vs. Warfarin among Patients with Nonvalvular AtrialFibrillation and Venous Thromboembolism in the U.S.
TLDR
Economic evaluations have consistently shown that medical costs are reduced when TSOACs are used instead of warfarin for the treatment of NVAF or VTE, with apixaban being associated with the greatest reduction in medical costs.
Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States
  • S. Deitelzweig, Jennifer D. Guo, +10 authors A. Nadkarni
  • Medicine
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • 2018
TLDR
Compared to warfarin, apixaban treatment was associated with shorter index hospital stays, lower index hospitalization costs, and reduced risk of MB-related readmissions among hospitalized patients with VTE.
Bleeding Risk Assessment in Patients with Venous Thromboembolism.
The recommended treatment for patients with venous thromboembolism (VTE) is anticoagulation for at least 3 months. However, anticoagulant treatment increases the risk of bleeding, and patients at
Evaluation of medical costs avoided when new oral anticoagulants are used for extended treatment of venous thromboembolism based on clinical trial results
TLDR
Apixaban was associated with the greatest avoidance in medical costs, which was driven mainly by a greater reduced rate in recurrent VTE than other NOACs versus placebo and also a reduction in major bleeding rate.
An anticoagulant that does not cause bleeding – an abrupt stop on the road to the Holy Grail
TLDR
A completely different approach for potential safe anticoagu‐ lation was identified by chance in a patient who presented with a traumatic subdural hemorrhage and greatly prolonged global plasma coagulation test results due to an anti‐thrombin immunoglobulin A paraprotein.
Systematic literature review of treatment patterns for venous thromboembolism patients during transitions from inpatient to post-discharge settings
TLDR
Evidence on the use of direct oral anticoagulant treatments for venous thromboembolism in the US for patients transitioning from inpatient to post-discharge settings is summarized to identify the potential areas of opportunity to improve the management of VTE.
Resource utilization and charges of patients with and without diagnosed venous thromboembolism during primary hospitalization and after elective inpatient surgery: a retrospective study
TLDR
Patients undergoing elective inpatient surgical procedures with general anesthesia who had a VTE event during their primary hospitalization had a significantly longer length of stay and significantly higher total hospital charges than comparable patients without a V TE event.

References

SHOWING 1-10 OF 26 REFERENCES
All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.
TLDR
In this large matched-cohort study, VTE was associated with a 3.6% risk of hospital-documented recurrence and a 7.1%risk of PTS up to 1 year after index VTE.
Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations.
TLDR
The economic burden of DVT and PE in direct medical cost is large, due not only to the initial hospitalization event, but also to the high rate of hospital readmission (5%-14%), over half of which occurs within 90 days.
Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
OBJECTIVE To measure the per-event health plan costs for acute and follow-up treatment not directed by a clinical study protocol in a group of commercially insured patients in 2 managed care
Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study
TLDR
The data suggest that while the incidence rates of VTE remain high, and outcomes suboptimal, there have been marked changes in its management.
Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry.
TLDR
The occurrence of major bleeding in patients with VTE is outstanding in terms of overall mortality, fatal bleeding (18%) or re-bleeding (5.9%), however, these patients also have an increased incidence of recurrent VTE (4.9%) and fatal pulmonary embolism (1.2%).
Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates.
TLDR
The previously published DVT cost model was modified, updated and combined with the PE cost model to elucidate the same three categories of costs for VTE, and PE costs comprised a majority of the VTE costs.
Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients
TLDR
When any of the four NOACs are used instead of standard therapy for acute VTE, treatment medical costs are reduced, and Apixaban is associated with the greatest reduction in medical costs.
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
TLDR
Dabigatran has similar effects on VTE recurrence and a lower risk of bleeding compared with warfarin for the treatment of acute VTE.
Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study.
TLDR
Venous thromboembolism recurs frequently, especially within the first 6 to 12 months, and continues to recur for at least 10 years after the initial VTE, while VTE patients with transient or reversible risk factors are at less risk.
...
1
2
3
...